Plain-English translation of NCT06470347 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called pyrrolitinib maleate to see if it can help prevent early-stage or locally advanced HER2-positive breast cancer from coming back after you've finished your standard trastuzumab treatment. You would take this medication by mouth once a day for about one year. The goal is to find out whether this treatment is effective and safe for people in your situation.
Even after standard treatment with trastuzumab, some patients with HER2-positive breast cancer experience recurrence. This study is looking to see whether adding this medication for a year afterward might reduce that risk and improve long-term outcomes.
You would take one 400 mg tablet of the medication by mouth once daily with breakfast for about 52 weeks (one year). The study will monitor how well the medication works at preventing cancer recurrence and track any side effects through regular check-ins. The medication can be adjusted or paused if you experience side effects, and the research team will provide supportive medications (like anti-diarrheal agents) if needed during your treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China